Addition of Vandetanib to Standard Therapy (Pegliposomal Doxorubicin) in Patients With Recurrent Ovarian Cancer. A Multicentre Phase I / Randomized Phase II Study.
Phase of Trial: Phase I/II
Latest Information Update: 13 Oct 2016
At a glance
- Drugs Vandetanib (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ZACFAST
- 01 Jun 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2008-005557-38).
- 18 Feb 2011 Planned end date changed from 1 Feb 2011 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned end date changed from 1 Feb 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History